CA2568823A1 - Vaginally administrable progesterone-containing tablets and method for preparing same - Google Patents
Vaginally administrable progesterone-containing tablets and method for preparing same Download PDFInfo
- Publication number
- CA2568823A1 CA2568823A1 CA 2568823 CA2568823A CA2568823A1 CA 2568823 A1 CA2568823 A1 CA 2568823A1 CA 2568823 CA2568823 CA 2568823 CA 2568823 A CA2568823 A CA 2568823A CA 2568823 A1 CA2568823 A1 CA 2568823A1
- Authority
- CA
- Canada
- Prior art keywords
- tablet
- progesterone
- amount
- effervescent
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The present invention discloses a method for preparing a tablet for the vaginal administration of progesterone for systemic use. Tablets prepared by this method are also disclosed. Also disclosed are methods for vaginally administering such tablets three times a day to female patients being treated for infertility or other pregnancy-related conditions and disorders in an IVF program. In addition, disclosed are methods of administering a tablet containing 100 mg of natural progesterone at least three times per day to female patients who require stronger luteal support, e.g., older patients and overweight or obese patients, and patients in a donor oocyte program.
Claims (50)
1. A method of delivering progesterone to a female patient for hormone replacement therapy, which comprises placing in the vagina of said patient at least three times daily a tablet comprising progesterone as the active ingredient, pharmaceutically acceptable excipients or diluents, and an effervescent, and retaining said tablet in the vagina for a time efficacious to deliver said progesterone to said patient.
2. A method according to claim 1, wherein the progesterone in said tablet is present in an amount of at least about 50 mg.
3. The method according to claim 1, wherein the progesterone in said tablet is present in an amount of at least about 100 mg.
4. The method of claim 1, wherein the progesterone in said tablet is micronized.
5. The method of claim 1, wherein the effervescent in the tablet is present in an amount of about 5% to about 12% by weight of the tablet.
6. The method of claim 1, wherein the effervescent in the tablet is present in an amount of about 8% by weight of the tablet.
7. A method of delivering progesterone to a female patient, which comprises placing in the vagina of said patient at least three times daily a tablet comprising progesterone, a pharmaceutically acceptable excipient or diluent, and an effervescent, wherein said tablet is prepared by the steps of:
(i) mixing water with progesterone to obtain wetted progesterone in the absence of pharmaceutically acceptable excipients or diluents; and drying said wetted progesterone to form dry progesterone;
(ii) mixing said dry progesterone with (a) a pharmaceutically acceptable excipients or diluent and (b) an effervescent to form a mixture; and (iii) forming the tablet by direct compaction of said mixture, and retaining said tablet in said vagina until the tablet dissolves, wherein the tablet provides a T max upon dissolution of about six hours.
(i) mixing water with progesterone to obtain wetted progesterone in the absence of pharmaceutically acceptable excipients or diluents; and drying said wetted progesterone to form dry progesterone;
(ii) mixing said dry progesterone with (a) a pharmaceutically acceptable excipients or diluent and (b) an effervescent to form a mixture; and (iii) forming the tablet by direct compaction of said mixture, and retaining said tablet in said vagina until the tablet dissolves, wherein the tablet provides a T max upon dissolution of about six hours.
8. A method according to claim 7, wherein the progesterone in said tablet is present in an amount of at least about 50 mg.
9. A method according to claim 7, wherein the progesterone in said tablet is present in an amount of at least about 100 mg.
10. The method of claim 7, wherein the progesterone in said tablet is micronized.
11. The method of claim 7, wherein the effervescent in the tablet is present in an amount of about 5% to about 12% by weight of the tablet.
12. The method of claim 7, wherein the effervescent in the tablet is present in an amount of about 8% by weight of the tablet.
13. A method of delivering progesterone to a female patient, which comprises (a) placing in the vagina of the patient at least three times daily a vaginal tablet comprising micronized progesterone as the active ingredient, pharmaceutically acceptable excipients or diluents, and an effervescent; and (b) permitting the tablet to dissolve in the vagina, the tablet providing a T
max of about six hours upon dissolution.
max of about six hours upon dissolution.
14. A method according to claim 13, wherein the progesterone in said tablet is present in an amount of at least about 50 mg.
15. A method according to claim 13, wherein the progesterone in said tablet is present in an amount of at least about 100 mg.
16. The method of claim 13, wherein the progesterone in said tablet is micronized.
17. The method of claim 13, wherein the effervescent in the tablet is present in an amount of about 5% to about 12% by weight of the tablet.
18. The method of claim 13, wherein the effervescent in the tablet is present in an amount of about 8% by weight of the tablet.
19. A method of delivering progesterone to a female patient, comprising placing in the vagina of said patient at least three times daily a tablet consisting essentially of progesterone as the active ingredient, pharmaceutically acceptable excipients or diluents, and an effervescent, and retaining said tablet in the vagina for a time efficacious to deliver said progesterone to said patient.
20. The method according to claim 1, wherein said female patient is >=
about 35 years old.
about 35 years old.
21. The method according to claim 20, wherein said female patient is between about 35 and about 42 years old.
22. The method according to claim 1, wherein said female patient has a Body Mass Index (BMI) between about 25 and about 29 kg/m2.
23. The method according to claim 1, wherein said female patient has a Body Mass Index (BMI) that is >= about 30 kg/m2.
24. The method according to claim 1, wherein said female patient is >=
about 42 years old.
about 42 years old.
25. The method according to claim 1, wherein said female patient is undergoing donor oocyte treatment.
26. Use of a tablet three times daily in the vagina for delivering progesterone to a female patient for hormone replacement therapy, the tablet (i) comprising progesterone as the active ingredient, pharmaceutically acceptable excipients or diluents, and an effervescent; and (ii) retainable in the vagina for a time efficacious to deliver said progesterone to said patient.
27. The use according to claim 26, wherein the progesterone in said tablet is present in an amount of at least about 50 mg.
28. The use according to claim 26, wherein the progesterone in said tablet is present in an amount of at least about 100 mg.
29. The use of claim 26, wherein the progesterone in said tablet is micronized.
30. The use of claim 26, wherein the effervescent in the tablet is present in an amount of about 5% to about 12% by weight of the tablet.
31. The use of claim 26, wherein the effervescent in the tablet is present in an amount of about 8% by weight of the tablet.
32. Use of a tablet three times daily in the vagina for delivering progesterone to a female patient for hormone replacement therapy, the tablet comprising progesterone as the active ingredient, pharmaceutically acceptable excipients or diluents, and an effervescent and is prepared by the steps of:
(i) mixing water with progesterone to obtain wetted progesterone in the absence of pharmaceutically acceptable excipients or diluents; and drying said wetted progesterone to form dry progesterone;
(ii) mixing said dry progesterone with (a) a pharmaceutically acceptable excipients or diluent and (b) an effervescent to form a mixture; and (iii) forming the tablet by direct compaction of said mixture, wherein the tablet provides a T max upon dissolution of about six hours when retained in the vagina.
(i) mixing water with progesterone to obtain wetted progesterone in the absence of pharmaceutically acceptable excipients or diluents; and drying said wetted progesterone to form dry progesterone;
(ii) mixing said dry progesterone with (a) a pharmaceutically acceptable excipients or diluent and (b) an effervescent to form a mixture; and (iii) forming the tablet by direct compaction of said mixture, wherein the tablet provides a T max upon dissolution of about six hours when retained in the vagina.
33. The use according to claim 32, wherein the progesterone in said tablet is present in an amount of at least about 50 mg.
34. The use according to claim 32, wherein the progesterone in said tablet is present in an amount of at least about 100 mg.
35. The use of claim 32, wherein the progesterone in said tablet is micronized.
36. The use of claim 32, wherein the effervescent in the tablet is present in an amount of about 5% to about 12% by weight of the tablet.
37. The use of claim 32, wherein the effervescent in the tablet is present in an amount of about 8% by weight of the tablet.
38. Use of a tablet three times daily in the vagina for delivering progesterone to a female patient for hormone replacement therapy, the tablet (i) comprising comprising micronized progesterone as the active ingredient, pharmaceutically acceptable excipients or diluents, and an effervescent; and (ii) providing a T max of about six hours upon dissolution when retained in the vagina.
39. The use according to claim 38, wherein the progesterone in said tablet is present in an amount of at least about 50 mg.
40. The use according to claim 38, wherein the progesterone in said tablet is present in an amount of at least about 100 mg.
41. The use of claim 38, wherein the progesterone in said tablet is micronized.
42. The use of claim 38, wherein the effervescent in the tablet is present in an amount of about 5% to about 12% by weight of the tablet.
43. The use of claim 38, wherein the effervescent in the tablet is present in an amount of about 8% by weight of the tablet.
44. Use of tablet three times daily in the vagina for delivering progesterone to a female patient, the tablet (i) consisting essentially of progesterone as the active ingredient, pharmaceutically acceptable excipients or diluents, and an effervescent, and (ii) retainable in the vagina for a time efficacious to deliver said progesterone to said patient.
45. The use according to claim 26, wherein said female patient is >=
about 35 years old.
about 35 years old.
46. The use according to claim 45, wherein said female patient is between about 35 and about 42 years old.
47. The use according to claim 26, wherein said female patient has a Body Mass Index (BMI) between about 25 and about 29 kg/m2.
48. The use according to claim 26, wherein said female patient has a Body Mass Index (BMI) that is >= about 30 kg/m2.
49. The use according to claim 26, wherein said female patient is >=
about 42 years old.
about 42 years old.
50. The use according to claim 26, wherein said female patient is undergoing donor oocyte treatment.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/408,614 | 2006-04-20 | ||
| US11/408,614 US20060188571A1 (en) | 1998-11-18 | 2006-04-20 | Vaginally administrable progesterone containing tablets and method for preparing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2568823A1 true CA2568823A1 (en) | 2007-10-20 |
| CA2568823C CA2568823C (en) | 2012-02-07 |
Family
ID=38606770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2568823A Expired - Fee Related CA2568823C (en) | 2006-04-20 | 2006-11-24 | Vaginally administrable progesterone-containing tablets and method for preparing same |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2568823C (en) |
-
2006
- 2006-11-24 CA CA2568823A patent/CA2568823C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2568823C (en) | 2012-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2542779C2 (en) | Birth control technique used as and when necessary | |
| MX2008016508A (en) | Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders. | |
| KR20120044307A (en) | Pharmaceutical composition for emergency contraception | |
| KR100908161B1 (en) | Emergency contraception dosing method and pharmaceutical composition | |
| AU2006270749A1 (en) | Premature ovulation preventive agent | |
| US6207696B1 (en) | Compositions and methods for the prophylaxis and treatment of dysmenorrhea, endometriosis, and pre-term labor, using histidine | |
| KR20010012721A (en) | Combination therapy for modulating the human sexual response | |
| AU2013236960B2 (en) | Method for treating gynecological diseases | |
| NO324357B1 (en) | Use of an ostroprogestagen hormone preparation in the manufacture of a medicament for the treatment of estrogen disorders and osteoporosis in postmenopausal women, and the use of a pharmaceutical preparation in the manufacture of a medicament for stopping ovulation | |
| CN107151235B (en) | Use of thiadiazolidinedionyl GSK3 inhibitors for modulating sperm motility | |
| EP2419109B1 (en) | Method for on-demand contraception using levonorgestrel or norgestrel | |
| CN113347975A (en) | Montelukast for the treatment of erosive hand osteoarthritis | |
| CA2568823A1 (en) | Vaginally administrable progesterone-containing tablets and method for preparing same | |
| WO2010026469A1 (en) | Pharmaceutical composition for use in treating sexually transmitted infections | |
| Srivastava | Pharmacology: A book of achieving knowledge for drugs | |
| US20190262361A1 (en) | Progesterone Receptor Modulators for Use in the Therapy of Uterine Fibroids | |
| JP2004522783A (en) | Use of N-acetyl-D-glucosamine in the manufacture of a medicament for preventing and treating sexual dysfunction | |
| WO2023051780A1 (en) | Oral pharmaceutical composition | |
| US20230080934A1 (en) | Orodispersible formulations | |
| CA2680560C (en) | The use of ginsenoside rg1, its metabolites ginsenoside rh1 and/or ppt | |
| CN101919799B (en) | Novel sustained-release transdermal medicament delivery system | |
| WO2023284426A1 (en) | Anti-gout celery seed-flos sophorae immaturus extract and febuxostat pharmaceutical composition, and use thereof | |
| CN113116905A (en) | A composition for improving male sexual function and continuously improving sexual dysfunction, and its preparation method | |
| CN103054823A (en) | Solid preparation taking distigmine bromide as active ingredient | |
| CN115137809A (en) | Medicine containing adrenocorticotropic hormone and its derivative and its use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20201124 |